Encision, Inc. AEM(R) Technology Presented At AAGL

BOULDER, Colo., Nov. 17 /PRNewswire-FirstCall/ -- Encision Inc. , a medical device company with patented surgical technology emerging as a standard of care in minimally-invasive surgery, announced that results of a pilot study using its AEM technology in hysteroscopy were presented recently at the American Association of Gynecologic Laparoscopists (AAGL) congress in Chicago. The presentation, Stray Radiofrequency Currents During Resectoscopic Surgery May Be Safely Eliminated By Active Electrode Monitoring, was made by George A. Vilos, M.D., Professor of Surgery, from St. Joseph’s Health Care, The University of Western Ontario, London, Ontario, Canada.

Under an Institutional Review Board (IRB) approved study at the University of Western Ontario, a series of female patients underwent resectoscopic surgery using a conventional resectoscope adapted to AEM technology. The authors concluded, " ... baseline currents combined with the surges can produce heat loading that can cause (perineal/vaginal) burns. The adaptation of AEM may be effective in mitigating the hazards from insulation failure, capacitive coupling and directly coupled currents associated with the stray energy to the resectoscope.”

“We are pleased that Encision’s AEM technology has the potential to be applied to other areas of minimally invasive surgery to advance patient safety,” said Jack Serino, President & CEO of Encision. “Encision filed for three patents this year to cover additional applications for AEM and we will continue to explore a range of market opportunities for our technology.”

Encision Inc. designs and manufactures innovative surgical devices that allow the surgeon to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM(R) Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company’s actual results to differ materially include, among others, its ability to increase revenues through the Company’s distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company’s filings with the Securities and Exchange Commission.


Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com

Encision Inc.

CONTACT: Marcia McHaffie of Encision Inc., +1-303-444-2600,mmchaffie@encision.com